Agios Pharmaceuticals, Inc. is a biopharmaceutical company that pioneers therapies for rare diseases, with a focus on hemolytic anemias. The company is committed to building connections and cultivating relationships to create life-changing therapies for patients with rare diseases.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

COM:AGIOS

Agios Pharmaceuticals, Inc.

Last Close

54.62

21/11 21:00

Market Cap

2.47B

Beta: -

Volume Today

360.45K

Avg: -

market

industry

website

crunchbase

ipo date

peer of

competitor of

Metrics